Ann Clin Neurophysiol.  2022;24(1):26-29. 10.14253/acn.2022.24.1.26.

Lumbosacral polyradiculoneuropathy associated with combination therapy of nivolumab and ipilimumab

Affiliations
  • 1Department of Neurology, Gyeongsang National University Changwon Hospital, Changwon, Korea
  • 2Department of Neurology, College of Medicine, Gyeongsang Institute of Health Science, Gyeongsang National University, Jinju, Korea

Abstract

Immune checkpoint inhibitors (ICIs) have emerged as one of the most promising therapeutic options for advanced cancers. While ICIs have improved survival in multiple cancers, their increased use is restricted by various immune-related adverse events. In this report we describe a patient with renal cell carcinoma who received a combination of ICIs, nivolumab plus ipilimumab, and who developed lumbosacral polyradiculoneuropathy. Corticosteroid use was an effective treatment for this patient.

Keyword

Polyradiculoneuropathy; Drug-related side effects; Immune checkpoint inhibitors

Figure

  • Fig. 1. Sagittal and axial T2-weighted (A, C) and postcontrast T1-weighted (B, D) magnetic resonance imaging demonstrate thickened and enhanced cauda equina. The enhanced cauda equina is indicated by the arrow (B, D).


Reference

1. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016; 39:98–106.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10:909–915.
Article
3. Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018; 363:k4226.
Article
4. Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep. 2018; 18:3.
Article
5. Sheng IY, Ornstein MC. Ipilimumab and nivolumab as first-line treatment of patients with renal cell carcinoma: the evidence to date. Cancer Manag Res. 2020; 12:4871–4881.
6. Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2021; 4:755–765.
Article
7. Okada K, Seki M, Yaguchi H, Sakuta K, Mukai T, Yamada S, et al. Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. J Neurol. 2021; 268:680–688.
Article
Full Text Links
  • ACN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr